Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $14.04 Analyst target: $24.00 Upside: 70.94%
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.